Table 1.
Clinical and biological characteristics of the 152 patients with liver biopsy and of the 97 patients with all valid tests available and results on non-invasive tests.
| Variables | Liver biopsy (n = 152) | All valid tests available (n = 97) | NASH (n = 30) |
No NASH (n = 67) |
p value |
|---|---|---|---|---|---|
| Age, years, mean ± SD | 42 ± 11 | 41 ± 10 | 43 ± 9 | 40 ± 10 | 0.19 |
| Sex, women, n (%) | 128 (84) | 83 (86) | 19 (63) | 64 (96) | 1.0×10-4 |
| BMI, kg/m2, mean ± SD | 44.1 ± 5.3 | 44.4 ± 5.4 | 46.6 ± 5.8 | 43.4 ± 4.9 | 1.4×10-2 |
| WC, cm, mean ± SD | 124.6 ± 14.5 | 124.5 ± 14.2 | 131.3 ± 11.8 | 121.4 ± 14.2 | 6.9×10-4 |
| Hypertension, n (%) | 55 (36) | 33 (34) | 12 (40) | 21 (31) | 0.40 |
| Sleep apnea, n (%) | 85 (56) | 56 (58) | 22 (73) | 34 (51) | 3.7×10-2 |
| Diabetes, n (%) | 32 (21) | 16 (16) | 9 (30) | 7 (10) | 3.5×10-2 |
| Dyslipidemia, n (%) | 35 (23) | 21 (22) | 9 (30) | 12 (18) | 0.18 |
| Platelets (Giga/L) | 270 ± 63 | 273 ± 64 | 257 ± 67 | 280 ± 62 | 0.10 |
| ALT (IU/L) | 38.7 ± 21.6 | 38.5 ± 21.8 | 52.9 ± 27.5 | 32.1 ± 15.0 | 4.1×10-4 |
| AST (IU/L) | 23.9 ± 9.8 | 23.9 ± 9.5 | 28.7 ± 10.5 | 21.8 ± 8.3 | 2.6×10-3 |
| GGT (IU/L) | 45.4 ± 32.9 | 44.1 ± 31.9 | 57.3 ± 48.6 | 38.2 ± 18.2 | 4.5×10-2 |
| ALP (IU/L) | 83.2 ± 23.4 | 82.2 ± 25.8 | 85.4 ± 26.3 | 80.7 ± 25.6 | 0.41 |
| Bilirubin (μmol/L) | 11.0 ± 3.7 | 10.9 ± 3.9 | 11.7 ± 4.2 | 10.6 ± 3.8 | 0.37 |
| Prothrombin time (%) | 104 ± 8 | 103 ± 8 | 104 ± 7 | 102 ± 8 | 0.38 |
| Ferritin (μg/L) | 116 ± 110 | 118 ± 111 | 170 ± 134 | 95 ± 91 | 8.2×10-3 |
| Total cholesterol (mmol/L) | 5.1 ± 1.03 | 5.18 ± 1.04 | 5.21 ± 1.04 | 5.16 ± 1.04 | 0.85 |
| Triglycerides (mmol/L) | 1.45 ± 0.9 | 1.49 ± 0.8 | 1.86 ± 0.99 | 1.32 ± 0.6 | 9.0×10-3 |
| Glycated hemoglobin (%) | 5.89 ± 0.84 | 5.81 ± 0.68 | 6.10 ± 0.84 | 5.68 ± 0.56 | 1.7×10-2 |
| HOMA-IR | 6.27 ± 4.24 | 6.12 ± 3.97 | 7.98 ± 4.43 | 5.29 ± 3.47 | 5.1×10-3 |
| SteatoTest | 0.60 ± 0.17 | 0.60 ± 0.17 | 0.71 ± 0.12 | 0.56 ± 0.17 | 3.6×10-6 |
| Hepatic steatosis index | 59.6 ± 6.9 | 59.6 ± 7.3 | 64.0 ± 7.0 | 57.7 ± 6.5 | 1.0×10-4 |
| Fatty liver index | 45.4 ± 28.2 | 46.7 ± 28.6 | 64.4 ± 25.7 | 38.8 ± 26.3 | 3.5×10-5 |
| CAP (dB/m) | 325 ± 62 | 324 ± 63 | 351 ± 40 | 312 ± 68 | 7.1×10-4 |
| LSM (kPa) | 6.6 [4.6-9.5] | 6.2 [4.2-8.1] | 7.9 [5.9-8.9] | 5.4 [4.0-7.0] | 6.7×10-2 |
| MRI-PDFF (%) | 15.3 ± 10.5 | 15.9 ± 10.9 | 24.1 ± 8.2 | 12.2 ± 10.1 | 5.3×10-8 |
p values are those of the t tests between NASH and no NASH groups for each variable.
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CAP, controlled attenuation parameter; GGT, gamma-glutamyltransferase; HOMA-IR, homeostasis model assessment of insulin resistance; LSM, liver stiffness measurement; MRI-PDFF, MRI-proton density fat fraction; NASH, non-alcoholic steatohepatitis; WC, waist circumference.